That December, Gavi, the Vaccine Alliance, took the decision to provide funding for malaria vaccine programmes in eligible countries, thus opening the pathway for broader roll-out of the vaccine.
The landmark award, valued at up to 0 million, will lead to 18 million doses of the RTS,S vaccine being available over the next three years, potentially saving thousands of young lives annually.
‘Giant step forward’
Children in Kenya are the most vulnerable to Malaria infections.
In 2020, nearly half a million children died from malaria in Africa alone, a rate of one death per minute.https://t.co/Lcs5bAO2kX
The delivery of this malaria vaccine will bring hope to so many families.
Preventable disease
Meanwhile, WHO has welcomed progress in securing supply and timely access to the vaccine so that more countries can introduce it as soon as possible.
Last October, the UN health agency recommended its widespread use in countries with moderate to high malaria transmission.
CEO Seth Barkley reported that Gavi recently opened the “application window” for funding requests.
Pilot programme
GAVI
“Thanks to UNICEF’s procurement work, we now have more certainty on supply and can move a step further towards getting this life-saving vaccine to the people who need it the most. As manufacturing ramps up over time, we hope that increasing volumes will also lead to more sustainable, lower prices,” he said.
The RTS,S malaria vaccine – the result of 35 years of research and development – is the first-ever vaccine against a parasitic disease.
More than 30 countries have areas with moderate to high malaria transmission, according to data from the World Health Organization (WHO), and the vaccine could provide added protection to more than 25 million children each year once supply ramps up. “This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes”. Funding ‘window’ opened
UNICEF expects that demand for the malaria vaccine will be high among affected countries.
It was launched in a 2019 pilot programme, coordinated by WHO, in three countries – Ghana, Kenya and Malawi – which has reached more than 800,000 children.
Malaria remains one of the biggest killers of children under five. In 2020, nearly half a million boys and girls died from the disease in Africa alone, a rate of one death every minute.
Plans are already underway to boost production, including through technology transfer, UNICEF added, “so that every child at risk will one day have the opportunity to be immunized against this killer disease”.
High demand expected
As with any new vaccine, supply will be limited at first, the agency said, but will increase as manufacturing capacity ramps up over time, which in turn will lead to a decrease in costs per dose.
“Lives are at stake, every day,” said Dr. Kate O’Brien, Director of WHO’s Department of Immunization, Vaccines and Biologicals. “Given the initial limited supply, it is crucial that children living in areas where the risk of disease and need is highest are prioritized first”.
“We hope this is just the beginning. Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market,” she said.
